CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
September 2016—The Oncomine Lung Cell-Free DNA Assay from Thermo Fisher Scientific is designed to target mutations in non-small cell lung cancer samples derived from circulating cfDNA in blood. When combined with the company’s Ion S5 System, the research assay meets the need for a multi-targeted, next-generation-sequencing–based solution that enables highly sensitive detection across a broad set of gene variants.
Enabling analysis with as little as 1 ng of DNA obtained from a single tube of blood, the assay helps clinical researchers obtain results from the initial sample or samples collected over time from the same subject. Verification data using the assay shows 90 percent sensitivity and a greater than 98 percent specificity at 0.1 percent limit of detection.
The cfDNA assay is part of a comprehensive solution that enables sample to answer variant data analyses in a single workflow. By using tag sequencing, Ion Torrent informatics software detects and determines mutations to help limit the number of false-positive data points for single nucleotide variants and insertions-deletions detected at such low allele frequencies.
Thermo Fisher Scientific, 760-603-7200